RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Priority Review (China), Conditional marketing approval (European Union), Fast Track (European Union), Conditional marketing approval (China), Orphan Drug (Japan)

Structure/Sequence

Sequence Code 10256963L

Source: *****

Sequence Code 315617079L

Source: *****

Sequence Code 432311657H

Source: *****

Sequence Code 432311660H

Source: *****

Clinical Trials associated with Elranatamab

NCT06832865

/ Not yet recruitingPhase 2IIT

A Phase 2 Study of Elranatamab in Combination With Isatuximab (ELISA) in Relapsed and Refractory Multiple Myeloma

This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.

Start Date01 Aug 2026

Sponsor / Collaborator

The Massachusetts General Hospital

[+2]

NCT06988488

/ RecruitingPhase 1/2

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

Start Date07 Oct 2025

Sponsor / Collaborator

Celgene Corp.

NCT07190261

/ Not yet recruitingPhase 2IIT

A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

Glucocorticoids are the first-line treatment for wAIHA, but patients are prone to recurrence after dose reduction or discontinuation of glucocorticoids. Birgens et al. 's study found that approximately 55% of patients treated with prednisolone monotherapy experienced recurrence at 36 months. The overall response rate of second-line treatment with rituximab is 70-80%, but the recurrence rate reaches 50%. The response rates of other immunosuppressants, such as cyclosporine, cyclophosphamide, and azathioprine, are relatively low, approximately 30-50%. Patients with chronic hemolysis have recurrent episodes, which affect their survival and quality of life. New treatment methods need to be explored.

Start Date18 Sep 2025

Sponsor / Collaborator

Peking Union Medical College Hospital

100 Clinical Results associated with Elranatamab

100 Translational Medicine associated with Elranatamab

100 Patents (Medical) associated with Elranatamab

Literatures (Medical) associated with Elranatamab

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States

Article

Author: Garrison, Louis P. ; Fowler, Jessica ; Van Sanden, Suzy ; Marshall, Alex ; Lin, Dee ; Wu, Bingcao ; Le, Hoa H. ; Paner, Agne ; Goble, Joe ; Gordan, Lucio N. ; Mu, Fan ; Bensimon, Arielle G. ; Ammann, Eric ; Zhang, Xinke ; Min, Elissa E. ; Kim, Nina

AIMS:

Teclistamab and elranatamab are bispecific antibodies recently approved for the treatment of triple class-exposed relapsed/refractory multiple myeloma (RRMM). This study assessed the relative efficacy and economic value of teclistamab and elranatamab through a matching-adjusted indirect comparison (MAIC) and cost per responder analysis using data from the MajesTEC-1 (NCT03145181/NCT04557098) and MagnetisMM-3 (NCT04649359) trials.

MATERIALS AND METHODS:

The MAIC compared overall response rate (ORR) between the therapies after weighting individual patient data from MajesTEC-1 to match key baseline characteristics in MagnetisMM-3. Matched covariates included age, refractory status, prior lines of therapy, extramedullary disease, performance status, disease stage, and cytogenetic risk profile. Cost per responder was calculated based on estimated per-patient drug acquisition and administration cost (2024 United States dollars) over 6 months divided by ORR. One-way and probabilistic sensitivity analyses were conducted to characterize uncertainty.

RESULTS:

The ORRs were 63.0% for teclistamab before matching (N = 165), 61.4% for teclistamab after matching (effective sample size = 92), and 61.0% for elranatamab (N = 123) (odds ratio after matching: 1.02; 95% confidence interval [CI]: 0.59, 1.77). Per-patient costs were estimated to be $231,435 for teclistamab and $285,201 for elranatamab (difference: -$53,766; 95% confidence interval [CI]: -$59,094, -$48,311), yielding costs per responder of $376,930 and $467,730, respectively (difference: --$90,800; 95% CI: -$183,680, $8,148).

LIMITATIONS:

Because MajesTEC-1 and MagnetisMM-3 are single-arm trials, the MAIC was unanchored and therefore susceptible to confounding from any unadjusted effect modifiers or prognostic variables.

CONCLUSIONS:

Teclistamab was associated with significantly lower treatment costs and numerically lower cost per responder than elranatamab in triple class-exposed RRMM.

16 Oct 2025·BLOOD

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Article

Author: Vianna, Pedro ; Miller, Shannon ; Hossain, Shahrier ; Cuddy, Sarah A. M. ; Lentzsch, Suzanne ; Rossi, Annemarie ; Bianchi, Giada ; Bhutani, Divaya ; Falk, Rodney H. ; Laubach, Jacob P. ; Chakraborty, Rajshekhar

Abstract:

Immunoglobulin light-chain (AL) amyloidosis is a plasma cell disorder characterized by progressive organ dysfunction secondary to deposition of organized immunoglobulin light-chain aggregates. Achievement of rapid and deep normalization of involved immunoglobulin free light chains is necessary to maximize chances of reversibility of organ dysfunction, which, in turn, results in improved quality and length of life. There are no US Food and Drug Administration (FDA)–approved therapies for patients with relapsed AL amyloidosis. B-cell maturation antigen–targeting (BCMA)-bispecific T-cell engagers teclistamab and elranatamab have shown high activity and acceptable safety profile in patients with relapsed and/or refractory multiple myeloma, leading to their FDA approval. Herein, we report on safety and efficacy of elranatamab for patients with relapsed and/or refractory AL amyloidosis. We treated 9 consecutive patients with advanced-stage AL amyloidosis with single-agent elranatamab, observing a 100% overall response and 67% complete response rate, including minimal residual disease negativity, with expected toxicities. Median time to hematological response was 9 days (range, 6-24), with deep suppression in involved free light chains observed within 1 cycle of therapy, translating in cardiac and renal responses at 3 to 6 months. These data support prospective studies exploring elranatamab for patients with relapsed AL amyloidosis.

14 Oct 2025·Blood Advances

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies

Article

Author: Landgren, Ola ; Kazandjian, Dickran ; Diamond, Benjamin ; Kowalski, Andrew ; Coffey, David ; Pandey, Abhishek ; Lykon, Jill ; Maura, Francesco ; Kaddoura, Marcella ; Hoffman, James

Abstract:

Bispecific antibodies for treatment for multiple myeloma are highly effective but commonly cause cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Emerging data indicate that prophylactic tocilizumab may reduce CRS, without impacting efficacy. We administered a single dose of tocilizumab before the first dose of bispecific antibodies to 119 patients to determine the impact on CRS in a real-world setting including B-cell maturation antigen × CD3– and G-protein–coupled receptor class C group 5 member D × CD3–targeted antibodies. The best overall response rate was 65.7% (binomial 95% confidence interval [CI], 55.8-74.7). We observed a low overall rate of CRS (10.1%; 95% CI, 5.3-17). For teclistamab, elranatamab, linvoseltamab, and talquetamab individually, the CRS rate was 8.9%, 12.5%, 0%, and 13%, respectively. The overall rate of ICANS (5.9%; 95% CI, 2.4-11.7) was low but similar to rates without prophylactic tocilizumab. CRS was limited to grade 1 for 10 of 12 events. There were no grade 3 CRS events, and no additional doses of tocilizumab or corticosteroids were given for CRS. Our real-world evidence results suggest that tocilizumab may be effective as a preventive, rather than reactive, measure to prevent CRS without compromising efficacy.

News (Medical) associated with Elranatamab

17 Oct 2025

·www.prnewswire.com

Precision Oncology Approaches Drive $312B Market Transformation

USA News Group News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates across oncology as companies advance novel mechanisms targeting previously difficult populations, with recent clinical data demonstrating high response rates in molecularly defined patient subgroups while FDA priority reviews compress development timelines for innovative platforms1. Multi-cancer early detection blood tests have correctly identify two thirds of cancers with a single blood draw and pinpoint the original cancer site in 85% of cases, detecting over 50 cancer types including 47 that lack recommended screening today while simplifying diagnosis processes that traditionally require expensive tests or invasive biopsies2. This convergence of targeted protein degraders, early detection diagnostics, immune activation platforms, and bispecific antibodies positions GT Biopharma, Inc. (NASDAQ: GTBP), Nurix Therapeutics, Inc. (NASDAQ: NRIX), GRAIL, Inc. (NASDAQ: GRAL), C4 Therapeutics, Inc. (NASDAQ: CCCC), and Pfizer, Inc. (NYSE: PFE). According to Precedence Research, the global precision oncology market reached $133 billion in 2025 and is predicted to surpass $312 billion by 2034, driven by increasing cancer prevalence and continuous advancement in genomic profiling techniques allowing more accurate and personalized therapies3. Regulatory agencies increasingly approve therapies for earlier disease stages while expanding patient populations through label expansions, creating favorable conditions for companies developing targeted degraders eliminating undruggable proteins, blood tests enabling intervention before symptoms appear, and combination strategies pairing novel mechanisms with established immunotherapy platforms4. GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company headquartered in San Francisco that's focused on harnessing the power of the immune system to fight cancer. The firm is currently advancing innovative immunotherapy treatments designed to combat some of the most challenging cancer types, with recent progress showing promise in its ongoing Phase 1 clinical trial of GTB-3650. The company has successfully enrolled both patients in the trial's third dosing group (Cohort 3), with neither patient experiencing concerning side effects or dose-limiting toxicities thus far. GT Biopharma expects to commence treatment for Cohort 4 patients before the end of 2025, with further data releases planned for early 2026. The Phase 1 study is testing GTB-3650 in patients battling relapsed or refractory blood cancers that express the CD33 protein, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These represent some of the most difficult cancer cases to treat, involving patients whose disease either came back after initial therapy or never responded to conventional treatment options. GTB-3650 works by stimulating the patient's natural killer cells, a type of immune cell that naturally hunts down and destroys abnormal cells, to specifically target cancer cells. Patients receive the therapy through continuous infusions following a structured schedule: two weeks of treatment followed by two weeks of rest, repeating this cycle for up to four months based on how they respond. After thorough safety assessments, the company successfully advanced into Cohort 3 following formal reviews of the initial two patient cohorts that found no safety or tolerability issues. The early results are particularly encouraging based on biomarker data, objective biological measurements that indicate whether the drug is working as designed. Blood analysis from the first four patients revealed measurable increases in both natural killer cell activity and proliferation. The initial patient in Cohort 3 has shown encouraging signs of immune activation at levels comparable to those seen in patients from the earlier, lower-dose cohorts. This biological response suggests GTB-3650 is functioning precisely as intended: activating the immune system and directing it to attack cancer cells. The Phase 1 design calls for testing GTB-3650 in approximately 14 patients across seven cohorts, with two patients per cohort receiving progressively higher doses from 1.25μg/kg/day in Cohort 1 up to 100μg/kg/day in Cohort 7. The trial will continue escalating doses into higher ranges expected to translate immune activation into meaningful clinical benefits. "We are pleased with the enrollment momentum in our Phase 1 clinical trial evaluating GTB-3650 in cancer patients, which continues to advance on schedule," said Michael Breen, Executive Chairman and CEO of GT Biopharma. "Moving into the third dose cohort after a successful safety review and encouraging early evidence of immunological activity, mark important steps forward in the development of GTB-3650. We look forward to sharing more data later this year to reinforce the ability of our TriKE constructs to activate endogenous NK cells, and the potential for broader utility with other targets to treat solid tumors (GTB-5550) and autoimmune indications (GTB-7550)." Beyond blood cancers, the company is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and prostate cancers. GT Biopharma plans to file its regulatory application to begin human trials of GTB-5550 in the fourth quarter of 2025. GTB-5550 is being designed as a subcutaneous injection that patients might eventually self-administer at home. Both candidates utilize GT Biopharma's proprietary TriKE platform technology, which employs specialized antibody fragments originally found in camels and llamas. These molecules offer advantages over conventional antibodies due to their smaller size and greater stability. The company holds an exclusive worldwide license from the University of Minnesota for this technology. As of June 30, 2025, GT Biopharmareported approximately $5.3 million in cash and cash equivalents, with management projecting this capital would support operations through the first quarter of 2026. CONTINUED… Read this and more news for GT Biopharma, Inc. at: Nurix Therapeutics, Inc. (NASDAQ: NRIX) has outlined pivotal trial plans for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia, reporting an 80.9% objective response rate in Phase 1a data presented at the Society of Hematologic Oncology 2025 Annual Meeting. The company reported third quarter 2025 revenue of $7.9 million and maintained a strong cash position of $428.8 million as of August 31, 2025. "Nurix is preparing to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL patients in the fourth quarter of 2025 and we have outlined our plans for potential accelerated approval with a single arm study as well as a confirmatory randomized control Phase 3 study for full approval," said Arthur T. Sands, M.D., Ph.D., CEO of Nurix Therapeutics. "With a strong wholly owned pipeline and world-class partnerships, Nurix is well positioned to establish degrader-based medicines as a new standard of care in both cancer and autoimmune diseases." The company's pipeline advancement includes preclinical data for GS-6791, an IRAK4 degrader developed in collaboration with Gilead Sciences, presented at the European Academy of Dermatology and Venereology 2025 Congress. Nurix continues to advance its autoimmune disease programs, including a STAT6 degrader with Sanofi currently in IND-enabling studies. GRAIL, Inc. (NASDAQ: GRAL) has announced a strategic collaboration with Samsung C&T and Samsung Electronics to commercialize its Galleri multi-cancer early detection test across key Asian markets. Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per share, with Samsung C&T serving as the exclusive distributor in South Korea, with potential expansion to Japan and Singapore. "We look forward to partnering with Samsung to bring multi-cancer early detection to Asia, beginning in South Korea," said Sir Harpal Kumar, President, International Business & Biopharma, at GRAIL. "Samsung's significant equity investment strengthens our balance sheet and provides further cash runway as we advance through key milestones to secure reimbursement for Galleri in the U.S. and key international markets." The Galleri test can detect more than 50 types of cancer with a simple blood draw before symptoms appear, doubling the number of cancers detected when added to standard screening protocols. The investment is subject to execution of definitive collaboration agreements and is expected to close in early 2026, with commercial operations beginning soon after. C4 Therapeutics, Inc. (NASDAQ: CCCC) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate the combination of cemsidomide and elranatamab for treating relapsed/refractory multiple myeloma. Under the agreement, Pfizer will supply elranatamab (ELREXFIO), a BCMAxCD3 targeted bispecific antibody, at no cost for C4 Therapeutics' upcoming Phase 1b trial expected to initiate in Q2 2026. "We look forward to initiating this trial to evaluate cemsidomide in combination with elranatamab in the hopes we can develop a new treatment regimen and potentially improve outcomes for multiple myeloma patients in earlier lines of therapy," said Andrew Hirsch, CEO of C4 Therapeutics. "Our supply agreement with Pfizer creates an opportunity for cemsidomide to be combined with elranatamab, which is on the path to potentially becoming a standard of care BCMAxCD3 bispecific in a growing market." The Phase 1b trial will evaluate cemsidomide, an IKZF1/3 degrader, combined with dexamethasone and elranatamab as second-line or later therapy, seeking to establish an optimal dose for the combination. Data from the cemsidomide Phase 1 trial demonstrated robust T-cell activation and cytokine expression, suggesting the combination may amplify anti-myeloma immune response when paired with BCMAxCD3 bispecific antibodies. Article Sources: CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by USA News Group on behalf of Market IQ Media Group Inc. ("MIQ"). MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Digital Media Group ("CDMG"). There may be 3rd parties who may have shares of GT Biopharma, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of GT Biopharma, Inc. but reserve the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved on behalf of GT Biopharma, Inc. by CDMG; this is a paid advertisement, we currently own shares of GT Biopharma, Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES: Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1ImmunotherapyPhase 3ASCOLicense out/in

16 Oct 2025

·ir.c4therapeutics.com

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up to an Additional $225 Million in Proceeds WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the pricing of an underwritten offering to a select group of institutional investors consisting of 21,895,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 28,713,500 shares of its common stock. Each share of common stock and each pre-funded warrant is accompanied by a Class A Warrant and a Class B Warrant, each to purchase one share of common stock (or pre-funded warrant in lieu thereof) at an exercise price of $2.22 per share. The offering was led by RA Capital Management with participation from existing shareholders including OrbiMed, Soleus Capital, Lynx1 Capital Management, and Bain Capital Life Sciences. The Class A Warrants are exercisable at any time through the earlier of (i) 30 days after the achievement of a trigger tied to the clinical results from the planned Phase 1b trial of cemsidomide with elranatamab, or (ii) five years from the date of issuance. The Class B Warrants are exercisable at any time prior to the fifth anniversary of the date of issuance and, under certain circumstances based on stock appreciation, C4T may require the mandatory exercise of the warrants. The shares of common stock (with accompanying Class A and Class B Warrants) are being sold at a combined price of $2.47 per share of common stock and accompanying warrants, and the pre-funded warrants (with accompanying Class A and Class B Warrants) are being sold at a combined price of $2.4699 per pre-funded warrant and accompanying warrants, which represents the per share price of the common stock less the $0.0001 per share exercise price for each pre-funded warrant. All securities in the offering are being sold by C4T. The aggregate gross proceeds to C4T from the offering, before deducting underwriting discounts and commissions and offering expenses and excluding any proceeds from potential exercise of the Class A and Class B Warrants and nominal proceeds from potential exercise of the pre-funded warrants, are expected to be $125.0 million. If all Class A and Class B Warrants and pre-funded warrants are exercised, the aggregate gross proceeds to C4T from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $349.7 million. The offering is expected to close on or about October 17, 2025, subject to the satisfaction of customary closing conditions. Together with its existing cash and cash equivalents and marketable securities, C4T intends to use the net proceeds of the offering to primarily fund its ongoing and planned clinical trials of cemsidomide, other research and development activities, and for working capital and general corporate purposes. Jefferies, TD Cowen and Evercore ISI are acting as book-running managers for the offering. The securities were offered by C4T pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024 and declared effective by the SEC on November 13, 2024 (File No. 333-282933). The prospectus supplement, accompanying prospectus and any free writing prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the prospectus supplement, accompanying prospectus and any free writing prospectus relating to the offering may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at TDManualrequest@broadridge.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering will be made only by means of the prospectus supplement and the accompanying prospectus. About C4 TherapeuticsC4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the timing of the closing of the offering, the anticipated use of proceeds from the offering and the potential for any future proceeds to C4T from the exercise of the Class A and Class B Warrants and pre-funded warrants. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in C4T’s most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q and in its subsequent filings filed with the Securities and Exchange Commission, including the prospectus supplement, accompanying prospectus and any free writing prospectus relating to the offering. All forward-looking statements contained in this press release speak only as of the date on which they were made. C4T undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contacts:Investors:Courtney SolbergAssociate Director, Investor RelationsCSolberg@c4therapeutics.com Media:Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com

Phase 1

01 Oct 2025

·ir.c4therapeutics.com

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phase 1b trial. The Phase 1b trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for patients with multiple myeloma. This Phase 1b trial, which is expected to initiate in Q2 2026, will seek to establish an optimal dose for cemsidomide in combination with elranatamab. Under the terms of the agreement, Pfizer will supply elranatamab at no cost while C4T will sponsor and conduct the trial. “We look forward to initiating this trial to evaluate cemsidomide in combination with elranatamab in the hopes we can develop a new treatment regimen and potentially improve outcomes for multiple myeloma patients in earlier lines of therapy,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “Our supply agreement with Pfizer creates an opportunity for cemsidomide to be combined with elranatamab, which is on the path to potentially becoming a standard of care BCMAxCD3 bispecific in a growing market.” Data generated from the cemsidomide Phase 1 trial in relapsed/refractory multiple myeloma demonstrate robust T-cell activation and cytokine expression across multiple doses. By activating immune T-cells, cemsidomide, when combined with a BCMAxCD3 bispecific such as elranatamab, may amplify the anti-myeloma immune response and lead to higher quality of responses. About C4 TherapeuticsC4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com. About CemsidomideCemsidomide is an investigational, orally bioavailable small-molecule degrader in clinical development for the treatment of relapsed/refractory multiple myeloma. Data from the Phase 1 trial, which has completed enrollment, demonstrate cemsidomide’s differentiated safety and tolerability profile and class-leading anti-myeloma activity that together support the potential for durable outcomes. Two clinical trials are planned to further evaluate cemsidomide in relapsed/refractory multiple myeloma: a Phase 2 single-arm registrational trial to evaluate cemsidomide in combination with dexamethasone, which is expected to initiate in Q1 2026; and a Phase 1b trial to evaluate the safety and tolerability of cemsidomide and dexamethasone in combination with elranatamab, which is expected to initiate in Q2 2026. Forward-Looking StatementsThis press release contains “forward-looking statements” of C4 Therapeutics, Inc., within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement or cohort initiation; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to replicate interim or early-stage results from our clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials; the potential timing for updates on our clinical and research programs; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that the results of preclinical studies and/or clinical trials will or will not be predictive of results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and C4 Therapeutics undertakes no duty to update this information unless required by law. Contacts:Investors:Courtney SolbergAssociate Director, Investor RelationsCSolberg@c4therapeutics.com Media:Loraine SpreenSenior Director, Corporate Communications & Patient AdvocacyLSpreen@c4therapeutics.com

Phase 1License out/inPROTACs

100 Deals associated with Elranatamab

External Link

KEGG	Wiki	ATC	Drug Bank
D12058	-	-	DB15395

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Myeloma	United States	Pfizer Inc.	14 Aug 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Relapse multiple myeloma	Phase 3	United States	Pfizer Inc.	08 Feb 2024
Relapse multiple myeloma	Phase 3	Japan	Pfizer Inc.	08 Feb 2024
Relapse multiple myeloma	Phase 3	Argentina	Pfizer Inc.	08 Feb 2024
Relapse multiple myeloma	Phase 3	Australia	Pfizer Inc.	08 Feb 2024
Relapse multiple myeloma	Phase 3	Belgium	Pfizer Inc.	08 Feb 2024
Relapse multiple myeloma	Phase 3	Brazil	Pfizer Inc.	08 Feb 2024
Relapse multiple myeloma	Phase 3	Canada	Pfizer Inc.	08 Feb 2024
Relapse multiple myeloma	Phase 3	Croatia	Pfizer Inc.	08 Feb 2024
Relapse multiple myeloma	Phase 3	Czechia	Pfizer Inc.	08 Feb 2024
Relapse multiple myeloma	Phase 3	Denmark	Pfizer Inc.	08 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2025	Not Applicable	Multiple Myeloma	-	Anti-BCMA (Teclistamab and Elranatamab)	hwtrkivjbx(scpqwdrbkn) = zubvurgwcj iimpooccqn (thaewazqvx ) View more	Positive	30 May 2025
				Anti-GPRC5D (Talquetamab)	hwtrkivjbx(scpqwdrbkn) = pmxhbzgfqy iimpooccqn (thaewazqvx ) View more
NCT05623020 (MagnetisMM-6, ASCO2025)	Phase 3	Multiple Myeloma BCMA-CD3	37	Elranatamab + Daratumumab + Lenalidomide	pkhiaqtbkr(ttztgaevme) = 1 case of G2 ICANS was reported fpwdgzzwcf (zbnzapiimo ) View more	Positive	30 May 2025
BOSS program (ASCO2025)	Not Applicable	Multiple Myeloma LDH \| ferritin \| cytopenia	43	elranatamab (BOSS program)	laxheqpfed(upmvfjnyhz) = keciwewmgy svvnfdwcrd (cupedxmbpx ) View more	Positive	30 May 2025
				elranatamab (iSUD program)	laxheqpfed(upmvfjnyhz) = ofbrdprdyg svvnfdwcrd (cupedxmbpx ) View more
NCT04649359 (MagnetisMM-3, ASCO2025)	Phase 2	Refractory Multiple Myeloma	47	ELRA 76 mg QW	nlahwlonlu(vstmopdffe) = 100% pts reported any grade treatment-emergent adverse events spfofgsnck (ebqwavswbi ) View more	Positive	30 May 2025
PF796 (EHA2025)	Phase 2	Multiple Myeloma	40	Elranatamab	tyzlvmwbvw(kjppnmljbe) = fjafbjwrjq ttpspebosf (zzonslbjaa, 59 - 89) View more	-	14 May 2025
NCT04649359 (MagnetisMM-3, EHA2025)	Phase 2	Multiple Myeloma BCMA	184	Elranatamab	ansjjqcpyr(ebplrzwyyj): least square mean difference = -11.22 (95% CI, -19.48 to -2.9)	Positive	14 May 2025
				Physician’s choice of therapy
ALTITUDE-1 (EHA2025)	Not Applicable	Multiple Myeloma	59	ELRA	swwvuokqqa(ddvptcqjpw) = yoboqzzvwh kmgscyyqvw (mfwyonjodz ) View more	-	14 May 2025
NCT04649359 (MagnetisMM-3, EHA2025)	Phase 2	Refractory Multiple Myeloma	47	ELRANATAMAB (ELRA)	jjorpkfeyi(fphocqoxin) = 100% of patients experienced any grade treatment-emergent adverse events vsluebwowl (icirfedrya ) View more	Positive	14 May 2025
NCT04649359 (MagnetisMM-3, EHA2025)	Phase 2	Refractory Multiple Myeloma BCMA	123	Elranatamab arm	qdyhuyxebn(gwvqgloefa) = xwvonjzerj rsbuahgqui (kyepfeswpb, NE) View more	Positive	14 May 2025
				Elranatamab (RW cohort)	qdyhuyxebn(gwvqgloefa) = smubaqhxgc rsbuahgqui (kyepfeswpb, 4.44 - 9.46) View more
PB3004 (EHA2025)	Not Applicable	Cytokine Release Syndrome \| Infectious Diseases TP53 loss \| del(17p)	14	Elranatamab	hmjbozpujq(ltpovrrmav) = One patient died of multi-organ failure due to progressive myeloma and concomitant infection following a single cycle elranatamab wdablzgfom (fdnkwyxfsj ) View more	-	14 May 2025
				Immunoglobulin replacement therapy

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis